Primary systemic amyloidosis: A brief overview

Area of Science:

• Hematology
• Oncology
• Nephrology

Background:

• Primary systemic amyloidosis, or light chain (AL) amyloidosis, is a rare lymphoproliferative disorder.
• Aberrant light-chain immunoglobulins aggregate into fibrils, depositing in tissues and causing organ damage.
• Untreated AL amyloidosis is fatal, necessitating comprehensive understanding and management.

Purpose of the Study:

• To provide a comprehensive summary of AL amyloidosis.
• To review the pathophysiology, clinical manifestations, and diagnostic approaches.
• To outline current treatment strategies and emerging areas of investigation.

Main Methods:

• Literature review of primary systemic amyloidosis.
• Synthesis of information on pathophysiology and clinical presentation.
• Summary of diagnostic criteria and treatment guidelines.

Main Results:

• AL amyloidosis results from the deposition of misfolded immunoglobulin light chains.
• Diagnosis involves identifying the underlying plasma cell clone and assessing organ involvement.
• Treatment aims to reduce the production of light chains and manage organ dysfunction.

Conclusions:

• AL amyloidosis is a complex systemic disease requiring multidisciplinary management.
• Early diagnosis and appropriate treatment are crucial for improving patient survival and quality of life.
• Ongoing research focuses on novel therapeutic targets and improved diagnostic tools.